Security
BioRestorative Therapies, Inc. Common Stock · BRTXD
BRTXDOTCCommon stockHistorical · closed Nov 5, 2021CIK 1505497Updated Oct 12, 2026
Name history
Stem Cell Assurance, Inc. · through Aug 16, 2011
Current security for this SEC filerBRTX · NASDAQ
BRTXD price & chart
Historical security
This listing closed Nov 5, 2021. Live provider charts are shown only for current listings.
Current security: BRTX
About the company
BioRestorative Therapies, Inc. (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. Our two core programs relate to the treatment of disc/spine disease (our lead cell therapy candidate, BRTX-100, is currently in a Phase 2 clinical trial for the treatment of chronic lumbar disc disease) and metabolic disorders (our ThermoStem® Program). We have also developed a commercial biocosmeceutical platform through which we formulate, manufacture and sell cell-based biologic aesthetic products.
In the news
No coverage from other publishers is available.
Recent filings
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Changes in Registrant's Certifying Accountant · Other Events
Items 4.01, 8.01, 9.01
Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Regulation FD Disclosure
Items 3.03, 5.03, 7.01, 9.01
Changes in Registrant's Certifying Accountant · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 4.01, 5.02, 9.01
Show 5 more recent filings
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Items 3.01, 9.01
NT 10-Q filing
Other Events
Items 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Items 5.02, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q3 2023 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 5,642,662Source | 14,573,451Source | 13,801,101Source | 8,516,559Source | 16,118,878Source | 4,640,279Source | 10,326,821Source | 17,951,466Source | 4,079,635Source | 12,279,799Source | — | 16,434,691Source |
| Property, Plant and Equipment, NetUSD | 309,498Source | 378,434Source | 306,310Source | 339,681Source | 345,807Source | 328,810Source | 369,992Source | 365,025Source | 358,767Source | 362,936Source | — | 261,003Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 556,634Source | 646,381Source | 736,128Source | 579,071Source | 668,818Source | 511,761Source | 601,508Source | 691,255Source | 534,198Source | 623,945Source | — | 803,438Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 602,444Source | 1,489,444Source | 2,436,869Source | 1,555,251Source | 2,252,247Source | 3,112,679Source | 1,228,789Source | 1,157,080Source | 1,511,188Source | 547,890Source | — | 1,676,577Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 13,400Source | 165,000Source | 39,300Source | 15,000Source | 27,400Source | 13,300Source | 25,000Source | 35,000Source | 15,500Source | 188,400Source | — | 16,000Source |
| Assets, CurrentUSD | 4,707,464Source | 13,508,939Source | 12,603,937Source | 7,597,807Source | 15,003,726Source | 3,799,708Source | 9,355,321Source | 16,770,263Source | 3,136,862Source | 11,144,221Source | — | 15,128,490Source |
| Prepaid Expense and Other Assets, CurrentUSD | 204,237Source | 233,697Source | 325,931Source | 201,871Source | 295,861Source | 194,378Source | 217,400Source | 316,963Source | 168,440Source | 223,230Source | — | 363,082Source |
| Operating Lease, Right-of-Use AssetUSD | — | 39,697Source | 154,726Source | — | 78,146Source | — | — | 115,385Source | — | — | — | 241,760Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | — | 4,581,535Source | 975,033Source | 3,671,235Source | 5,319,791Source | — | 4,182,080Source | 3,448,139Source | — | 3,748,406Source | 7,624,010Source | 602,619Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 797Source | 692Source | 468Source | 797Source | 692Source | 2,548Source | 750Source | 677Source | 887Source | 692Source | — | 369Source |
| Additional Paid in CapitalUSD | 168,905,254Source | 164,019,809Source | 177,042,781Source | 168,505,322Source | 163,735,564Source | 175,098,189Source | 167,148,523Source | 163,411,257Source | 170,262,565Source | 164,195,434Source | 149,895,596Source | 168,457,418Source |
| Retained Earnings (Accumulated Deficit)USD | -166,713,054Source | -154,042,567Source | -164,231,163Source | -163,674,777Source | -152,951,151Source | -172,075,095Source | -161,018,514Source | -148,922,589Source | -169,920,690Source | -155,678,715Source | -143,454,202Source | -152,640,897Source |
| Stockholders' Equity Attributable to ParentUSD | 2,206,979Source | 9,991,916Source | 10,760,891Source | 4,845,324Source | 10,799,087Source | 3,025,642Source | 6,144,741Source | 14,503,327Source | 356,744Source | 8,531,393Source | 6,456,954Source | 15,832,072Source |
| Liabilities and EquityUSD | 5,642,662Source | 14,573,451Source | 13,801,101Source | 8,516,559Source | 16,118,878Source | 4,640,279Source | 10,326,821Source | 17,951,466Source | 4,079,635Source | 12,279,799Source | 14,080,964Source | 16,434,691Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 3,435,683Source | 4,581,535Source | 932,619Source | 3,671,235Source | 5,319,791Source | 1,614,637Source | 4,182,080Source | 3,448,139Source | 3,722,891Source | 3,748,406Source | 7,500,474Source | 440,302Source |
| Operating Lease, Liability, CurrentUSD | — | 42,414Source | 156,310Source | — | 83,580Source | — | — | 123,536Source | — | — | — | 139,328Source |
| Accounts Payable, CurrentUSD | 859,898Source | 401,379Source | 227,355Source | 609,931Source | 215,920Source | 666,898Source | 599,500Source | 230,902Source | 1,341,495Source | 483,070Source | — | 170,902Source |
| Operating Lease, Liability, NoncurrentUSD | — | — | 42,414Source | — | — | — | — | — | — | — | — | 162,317Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | — | 682,237Source | 548,954Source | — | 447,622Source | — | — | 338,343Source | — | 744,485Source | — | 130,072Source |
| Preferred Stock, Value, Issued | —Source | —Source | — | —Source | —Source | — | —Source | — | — | — | — | — |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 52,394Source | 51,781Source | 209,985Source | 189,056Source | 165,735Source | 120,545Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 290,215Source | 2,009,126Source | 3,325,626Source | 2,812,566Source | 7,782,967Source | 12,612,862Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -2,200Source | -163,400Source | -172,900Source | 169,100Source | 3,300Source | 11,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | -682,003Source | 116,431Source | 839,525Source | 293,680Source | 18,487Source | 120,075Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -3,807,792Source | -2,778,786Source | -10,788,963Source | -8,230,346Source | -6,430,211Source | -5,870,761Source |
| Cash flows from investing activities: | ||||||||||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 968,447Source | 2,366,967Source | 8,897,470Source | 514,529Source | 3,252,043Source | -13,479,389Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | — | 36,400Source | 116,069Source | 106,189Source | 171,043Source | 265,223Source |
| Cash flows from financing activities: | ||||||||||||
| Payments for Repurchase of Common StockUSD | — | — | 0Source | — | 0Source | — | 0Source | — | 0Source | — | — | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 4,440,836Source | 1,092,718Source | 2,854,791Source | 7,379,330Source | 2,348,773Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 1,601,491Source | 680,899Source | 963,298Source | -336,487Source | -829,395Source | -19,350,150Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 399,932Source | 284,245Source | 468,708Source | 324,322Source | 290,215Source | 2,009,126Source | 3,325,626Source | 2,812,566Source | — | — |
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 89,747Source | 89,747Source | 89,746Source | 78,332Source |
| DepreciationUSD | — | — | — | — | — | — | — | — | 120,238Source | 99,309Source | 75,989Source | 42,212Source |
| Derivative, Gain (Loss) on Derivative, NetUSD | — | — | 612,064Source | 1,036,464Source | 574,591Source | -1,736,611Source | 1,220,121Source | -634,119Source | 1,121,502Source | 97,188Source | — | — |
| General and Administrative ExpenseUSD | — | — | 1,115,491Source | 1,048,987Source | 1,373,976Source | 1,097,417Source | 1,475,207Source | 2,182,725Source | 5,888,317Source | 6,579,413Source | 11,331,983Source | 15,580,473Source |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | — | — | — | — | — | — | — | — | — | 33,665Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,038,277Source | -1,091,416Source | -2,656,263Source | -4,028,562Source | -2,154,405Source | -5,339,799Source | -14,241,975Source | -8,979,381Source | -10,417,704Source | -18,494,769Source |
| Nonoperating Income (Expense)USD | — | — | 670,734Source | 1,195,577Source | 649,024Source | -1,559,755Source | 1,231,328Source | -532,265Source | 1,405,157Source | 2,575,813Source | 4,803,070Source | 479,256Source |
| Operating ExpensesUSD | — | — | 3,710,241Source | 2,502,350Source | 3,599,858Source | 2,551,417Source | 3,401,518Source | 4,829,625Source | 15,982,988Source | 11,928,122Source | 15,366,574Source | 19,093,825Source |
| Other Nonoperating Income (Expense)USD | — | — | 930Source | 566Source | 518Source | 911Source | 5,728Source | 1,246Source | 17,448Source | 150,850Source | 169,664Source | 107,088Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | — | 1,083,915Source | 3,096,250Source | — | 1,853,990Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | 42,411Source | 41,165Source | — | — | — |
| Interest Paid, Excluding Capitalized Interest, Operating Activities | — | — | — | — | — | — | —Source | — | — | — | — | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 11,800Source | 233,600Source | 303,300Source | 89,100Source | 23,170Source | 25,000Source | 359,700Source | 401,000Source | 145,800Source | 119,800Source |
| Cost of RevenueUSD | — | — | 10,570Source | 18,243Source | 8,729Source | 6,490Source | 7,385Source | 2,909Source | 23,844Source | 28,072Source | — | — |
| Operating Income (Loss)USD | — | — | -3,709,011Source | -2,286,993Source | -3,305,287Source | -2,468,807Source | -3,385,733Source | -4,807,534Source | -15,647,132Source | -11,555,194Source | -15,220,774Source | -18,974,025Source |
| Other Nonoperating Income (Expense)USD | — | — | 930Source | 566Source | 518Source | 911Source | 5,728Source | 1,246Source | 17,448Source | 150,850Source | 169,664Source | 107,088Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | — | — | — | — | — | — | -14,200,500Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -3,038,277Source | -1,091,416Source | -2,656,263Source | -4,028,562Source | -2,154,405Source | -5,339,799Source | -14,241,975Source | -8,979,381Source | -10,417,704Source | -18,494,769Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.33Source | -0.13Source | -0.3Source | -0.5Source | -0.12Source | -0.64Source | -1.58Source | -1.16Source | -2.47Source | -5.11Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.33Source | -0.13Source | -0.3Source | -0.5Source | -0.12Source | -0.64Source | -1.58Source | -1.16Source | -2.47Source | — |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 9,116,172Source | 8,121,499Source | 8,740,382Source | 8,121,499Source | 17,727,747Source | 8,357,143Source | 8,993,115Source | 7,763,932Source | 4,218,347Source | 3,617,858Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 9,116,172Source | 8,121,499Source | 8,740,382Source | 8,121,499Source | 17,727,747Source | 8,357,143Source | 8,993,115Source | 7,763,932Source | 4,218,347Source | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | — | — | — | — | 89,747Source | 89,747Source | 89,746Source | 78,332Source |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 52,394Source | 51,781Source | 209,985Source | 189,056Source | 165,735Source | — |
| General and Administrative ExpenseUSD | — | — | 1,115,491Source | 1,048,987Source | 1,373,976Source | 1,097,417Source | 1,475,207Source | 2,182,725Source | 5,888,317Source | 6,579,413Source | 11,331,983Source | 15,580,473Source |
| Gross ProfitUSD | — | — | 1,230Source | 215,357Source | 294,571Source | 82,610Source | 15,785Source | 22,091Source | 335,856Source | 372,928Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -14,200,500Source | — | — | — |
| Interest Income (Expense), NetUSD | — | — | 57,740Source | 158,547Source | 73,915Source | 175,945Source | — | 99,966Source | 266,207Source | 616,077Source | 552,293Source | 11,650Source |
| Nonoperating Income (Expense)USD | — | — | 670,734Source | 1,195,577Source | 649,024Source | -1,559,755Source | 1,231,328Source | -532,265Source | 1,405,157Source | 2,575,813Source | 4,803,070Source | 479,256Source |
| Operating ExpensesUSD | — | — | 3,710,241Source | 2,502,350Source | 3,599,858Source | 2,551,417Source | 3,401,518Source | 4,829,625Source | 15,982,988Source | 11,928,122Source | 15,366,574Source | 19,093,825Source |
| Research and Development ExpenseUSD | — | — | 2,594,750Source | 1,453,363Source | 2,225,882Source | 1,454,000Source | 1,926,311Source | 2,646,900Source | 10,094,671Source | 5,348,709Source | 4,034,591Source | 3,513,352Source |
Offerings
Registration 333-293322
- Gross proceeds
- 5000000.25
- Net proceeds
- 4650000.23
- Deal price
- 0.35
- Shares
- 14285715
- Offering price
- $0.35
- Ticker
- BRTX
Underwriters: Granted, Vested, Forfeited
Registration 333-291623
Filing attachments
ea030438901ex99-1.htm · 8-K · 2026-09-02
EX-99.1 3 ea030438901ex99-1.htm PRESS RELEASE, DATED SEPTEMBER 2, 2026 Exhibit 99.1 BioRestorative Therapies Announces Reverse Stock Split MELVILLE, N.Y., September 2, 2026 (GLOBE NEWSWIRE) - BioRestorative Therapies, Inc. (Nasdaq: BRTX) (“BioRestorative” or the “Company”), a late-stage clinical regenerative medicine company, today announced that the Company’s Board of Directors approved a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock (the “Common S…
Read attachment ↗ex99_1.htm · 8-K · 2026-06-12
EX-99.1 5 ex99_1.htm EX-99.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is made as of June 10, 2026 (the “Effective Date”), by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Francisco Silva (the “Executive”) (Company and Executive are collectively the “Parties”). Certain capitalized terms used in this Agreement are defined in Section 13. RECITALS WHEREAS, the Company and the Executive desire to enter into a…
Read attachment ↗ex99_1.htm · 8-K · 2026-05-29
EX-99.1 6 ex99_1.htm EX-99.1 LANCE ALSTODT EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is made as of May 27, 2026 (the “Effective Date”), by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Lance Alstodt (the “Executive”) (Company and Executive are collectively the “Parties”). Certain capitalized terms used in this Agreement are defined in Section 13. RECITALS WHEREAS, the Company and the …
Read attachment ↗ex99_2.htm · 8-K · 2026-05-29
EX-99.2 7 ex99_2.htm EX-99.2 ROBERT KRISTAL EMPLOYMENT AGREEMENT EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (this “Agreement”) is made as of May 27, 2026 (the “Effective Date”), by and between BioRestorative Therapies, Inc., a Nevada corporation (the “Company”), and Robert E. Kristal (the “Executive”) (Company and Executive are collectively the “Parties”). Certain capitalized terms used in this Agreement are defined in Section 13. RECITALS WHEREAS, the Company and…
Read attachment ↗ex107.htm · POS AM · 2026-04-20
Calculation of Filing Fee Tables S-1 BioRestorative Therapies, Inc. ──────────────────────────────────── Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable ─────────────────────────────────────────────────────────────────────────────── Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Pr…
Read attachment ↗ex99-1.htm · 8-K · 2026-02-17
Exhibit 99.1 BioRestorative Announces Pricing of $5.0 Million Public Offering MELVILLE, N.Y., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced the pricing of a public offering of 14,285,715 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to 14,285,715 shares…
Read attachment ↗